A World in
Need of Cures
Curative cell therapies are advancing—but their impact remains limited by the ability to manufacture high-quality human cells at scale. Existing production methods are expensive, require complex infrastructure, rely on expert operators, and compromise cell performance. As a result, these powerful therapies remain difficult to develop, and inaccessible to patients in need.
Harton was founded on the belief that the future of cell therapy depends on better biology from the start.
Instead of incrementally automating legacy approaches, we are building a new foundation for human cell manufacturing—one designed to preserve biological fidelity while scaling from development through GMP production.
By enabling reproducible, biology-first manufacturing, Harton helps cell therapy developers improve consistency, reduce cost per patient, and expand global access to life-changing treatments.
A World in
Need of Cures
Curative cell therapies are advancing—but their impact remains limited by the ability to manufacture high-quality human cells at scale. Existing production methods are expensive, require complex infrastructure, rely on expert operators, and compromise cell performance. As a result, these powerful therapies remain difficult to develop, and inaccessible to patients in need.
Harton was founded on the belief that the future of cell therapy depends on better biology from the start.
Instead of incrementally automating legacy approaches, we are building a new foundation for human cell manufacturing—one designed to preserve biological fidelity while scaling from development through GMP production.
By enabling reproducible, biology-first manufacturing, Harton helps cell therapy developers improve consistency, reduce cost per patient, and expand global access to life-changing treatments.
Unlocking the Next Era of Human Cell Manufacturing
OUR VISION
The future of cell production,
beyond the speed of disease,
scaled to treat every patient
Cell therapy is one of the most urgent examples of the challenge, but it is not the only one. Human cell production is rapidly becoming a central constraint of modern medicine, biological research, and biomanufacturing.
The next wave of breakthroughs depends on the ability to reliably produce high-quality human cells at scale. Harton is building a biology-first foundation for human cell manufacturing that expands what’s possible across this frontier.
Our fully-automated benchtop platform delivers human cells with biological fidelity, on demand, anywhere. From CAR-T to neurons and beyond, this foundation unlocks the next generation of biomedical research and cellular medicines.
Board of Directors
Advisors
Professor, Harvard Medical School
and MIT
Founding Core Faculty,
Wyss Institute at Harvard University
Laura Brass, PhD, MBA
Managing Director
Novartis Venture Fund
NEWS
Latest from Harton
